BIOTA PHARMACEUTICALS, INC. (NABI)

10.80
NASDAQ
Prev Close 10.80
Day Low/High 0.00 / 0.00
52 Wk Low/High 0.00 / 0.00
Exchange NASDAQ
Div & Yield N.A. (N.A)

Latest News

Mangrove Partners Agrees To Support Amended Transaction Between Nabi Biopharmaceuticals And Biota Holdings

Mangrove Partners Agrees To Support Amended Transaction Between Nabi Biopharmaceuticals And Biota Holdings

Says Improved Transaction Terms Are in Best Interest of Nabi Stockholders and Will Vote in Favor of All Transaction Proposals at Upcoming Special Meeting

Mangrove Partners Sends Letter To Stockholders Of Nabi Biopharmaceuticals

Mangrove Partners Sends Letter To Stockholders Of Nabi Biopharmaceuticals

Urges Fellow Stockholders to Vote Against the Ill-Advised & Value Destroying Transaction with Biota Holdings Limited at the Upcoming Special Meeting

NABI Biopharmaceuticals Inc. Stock Downgraded (NABI)

NABI Biopharmaceuticals (Nasdaq:NABI) has been downgraded by TheStreet Ratings from from a hold to sell.

NABI Stock Gaps Down On Today's Open (NABI)

Shares of NABI Biopharmaceuticals (Nasdaq:NABI) were gapping down Monday morning with an open price 64.5% lower than Friday's closing price. The stock closed at $5.63 yesterday and opened today's trading at $2.

NABI Biopharmaceuticals Inc. Stock Downgraded (NABI)

NABI Biopharmaceuticals (Nasdaq:NABI) has been downgraded by TheStreet Ratings from from a buy to hold.

Nabi Biopharmaceuticals Completes Enrollment Of Second NicVAX Phase III Clinical Trial

Final Data Expected in Early 2012 on Vaccine to Treat Nicotine Addiction and Prevent Smoking Relapse

10 Biotech Stocks Expected to at Least Double

The following 10 biotech stocks, though exceptionally risky, are expected to double, triple or quadruple in the next 12 months.

Nabi Biopharmaceuticals Significantly Enhances NicVAX Patent Portfolio

Patent Issued for Exclusive Use of NicVAX and Related Nicotine Vaccines to Treat or Prevent Nicotine Addiction

Nabi Biopharmaceuticals Completes Third PentaStaph(TM) Milestone

$8 Million Payment Due from GlaxoSmithKline Biologicals